Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Other Non-Current Assets: 2020-2025

Historic Other Non-Current Assets for Biofrontera (BFRI) over the last 4 years, with Sep 2025 value amounting to $472,000.

  • Biofrontera's Other Non-Current Assets rose 23.24% to $472,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $472,000, marking a year-over-year increase of 23.24%. This contributed to the annual value of $383,000 for FY2024, which is 20.54% down from last year.
  • According to the latest figures from Q3 2025, Biofrontera's Other Non-Current Assets is $472,000, which was down 11.78% from $535,000 recorded in Q2 2025.
  • In the past 5 years, Biofrontera's Other Non-Current Assets registered a high of $1.4 million during Q3 2021, and its lowest value of $268,000 during Q4 2021.
  • In the last 3 years, Biofrontera's Other Non-Current Assets had a median value of $418,500 in 2023 and averaged $423,600.
  • In the last 5 years, Biofrontera's Other Non-Current Assets tumbled by 71.38% in 2022 and then surged by 65.12% in 2025.
  • Biofrontera's Other Non-Current Assets (Quarterly) stood at $268,000 in 2021, then grew by 19.40% to $320,000 in 2022, then skyrocketed by 50.63% to $482,000 in 2023, then declined by 20.54% to $383,000 in 2024, then increased by 23.24% to $472,000 in 2025.
  • Its last three reported values are $472,000 in Q3 2025, $535,000 for Q2 2025, and $453,000 during Q1 2025.